Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Paula dos Santos Chaves"'
Autor:
Márcia Camponogara Fontana, João Víctor Laureano, Betielli Forgearini, Paula dos Santos Chaves, Bibiana Verlindo de Araujo, Ruy Carlos Ruver Beck
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 55
A specific, precise, and accurate LC-UV method was developed and validated to assay raloxifene hydrochloride in rat plasma. Raloxifene was analyzed after liquid-liquid extraction and quantified by reversed phase liquid chromatography (C18 column) usi
Externí odkaz:
https://doaj.org/article/1defd3c95d474127a3e132749831146a
Autor:
Paula dos Santos Chaves, Marc Schneider, Afra Torge, Luiza Abrahão Frank, Adriana Raffin Pohlmann, Ruy Carlos Ruver Beck, Silvia Stanisçuaski Guterres
Publikováno v:
Powder Technology. 354:348-357
The aim of this study was to produce redispersible spray-dried carvedilol-loaded nanocapsules and to evaluate their mucoadhesiveness as well as drug permeability performance the across sublingual mucosa in the presence or absence of simulated salivar
Autor:
Paula dos Santos Chaves, S.S. Guterres, J.H.R. dos Santos, Adriana Raffin Pohlmann, Ruy Carlos Ruver Beck
Publikováno v:
Pharmaceutical development and technology. 25(9)
The aim of this study was to propose the use of spray-dried mucoadhesive carvedilol-loaded nanocapsules in the formulation of sublingual tablets. There is no previous report describing the preparation of tablets containing spray-dried nanocapsules or
Autor:
Fernanda Visioli, Ruy Carlos Ruver Beck, Adriana Raffin Pohlmann, Paula dos Santos Chaves, Andréia Buffon, Silvia Stanisçuaski Guterres
Publikováno v:
Drug Development and Industrial Pharmacy. 45:63-66
Objective To evaluate, for the first time, the use of SCC4 cell monolayers as an alternative sublingual barrier model and study the influence of nanoencapsulation on carvedilol transport across SCC4 cell monolayers. Significance The sublingual cavity
Autor:
Paula dos Santos Chaves, Ruy Carlos Ruver Beck, Alex Nogueira Haas, João Lucas Campos de Oliveira
Publikováno v:
Current Pharmaceutical Design. 24:1377-1394
Polymeric nanoparticles are promising drug delivery systems due to their physicochemical properties, which may be explored to improve the treatment and prevention of several diseases, including oral conditions. Moreover, the pharmacological effects o
Autor:
Paula dos Santos Chaves, Adriana Raffin Pohlmann, Silvia Stanisçuaski Guterres, Ruy Carlos Ruver Beck, Alejandro Germán Frank, Luiza Abrahão Frank
Publikováno v:
AAPS PharmSciTech. 19:1637-1646
The use of polymers as mucoadhesive materials has been explored in several drug delivery systems. It is well known that the resulting mucoadhesiveness not only depends on the polymers by themselves, but also on the way they are delivered and on the a
Autor:
Silvia Stanisçuaski Guterres, Lucas Almeida Rigo, Adriana Raffin Pohlmann, Paula dos Santos Chaves, Carine Zuglianello, Ruy Carlos Ruver Beck, Diego Fontana de Andrade
Publikováno v:
Soft Materials. 16:20-30
This study proposes a novel blend of drying adjuvants (lactose and polyvinylpyrrolidone) as an approach to produce dispersible powders containing nanocapsules for the development of skin delivery s...
Autor:
Paula dos Santos Chaves, Ruy Carlos Ruver Beck, S.S. Guterres, Tatiele Katzer, Adriana Raffin Pohlmann
Publikováno v:
Journal of Nanoscience and Nanotechnology. 17:9286-9294
Autor:
Alexander Titz, Edilene Gadelha de Oliveira, Marc Schneider, Silvia Stanisçuaski Guterres, Paula dos Santos Chaves, Afra Torge, Ruy Carlos Ruver Beck, Stefanie Wagner, Adriana Raffin Pohlmann
Publikováno v:
International Journal of Pharmaceutics. 527:92-102
Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biologic
Autor:
Aline Ferreira Ourique, Silvia Stanisçuaski Guterres, Adriana Raffin Pohlmann, Paula dos Santos Chaves, Ruy Carlos Ruver Beck, Luiza Abrahão Frank
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 114:88-95
Carvedilol is a drug used to treat heart failure, hypertension, and coronary artery diseases . However, it has low oral bioavailability (25-35%) due to its high first-pass hepatic metabolism. The objective of this study was to develop carvedilol-load